@article{Oliver A. Cornely_Angelika Böhme_Dieter Buchheidt_Hermann Einsele_Werner J. Heinz_Meinolf Karthaus_Stefan W. Krause_William Krüger_Georg Maschmeyer_Olaf Penack_Jörg Ritter_Markus Ruhnke_Michael Sandherr_Michal Sieniawski_Jörg-Janne Vehreschild_Hans-Heinrich Wolf_Andrew J. Ullmann_2008, place={Pavia, Italy}, title={Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology}, volume={94}, url={https://haematologica.org/article/view/5125}, DOI={10.3324/haematol.11665}, abstractNote={There is no widely accepted standard for antifungal prophylaxis in patients with hematologic malignancies. The Infectious Diseases Working Party of the German Society for Haematology and Oncology assigned a committee of hematologists and infectious disease specialists to develop recommendations. Literature data bases were systematically searched for clinical trials on antifungal prophylaxis. The studies identified were shared within the committee. Data were extracted by two of the authors (OAC and MSi). The consensus process was conducted by email communication. Finally, a review committee discussed the proposed recommendations. After consensus was established the recommendations were finalized. A total of 86 trials were identified including 16,922 patients. Only a few trials yielded significant differences in efficacy. Fluconazole 400 mg/d improved the incidence rates of invasive fungal infections and attributable mortality in allogeneic stem cell recipients. Posaconazole 600 mg/d reduced the incidence of IFI and attributable mortality in allogeneic stem cell recipients with severe graft versus host disease, and in patients with acute myelogenous leukemia or myelodysplastic syndrome additionally reduced overall mortality. Aerosolized liposomal amphotericin B reduced the incidence rate of invasive pulmonary aspergillosis. Posaconazole 600 mg/d is recommended in patients with acute myelogenous leukemia/myelodysplastic syndrome or undergoing allogeneic stem cell recipients with graft versus host disease for the prevention of invasive fungal infections and attributable mortality (Level A I). Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II).}, number={1}, journal={Haematologica}, author={Oliver A. Cornely and Angelika Böhme and Dieter Buchheidt and Hermann Einsele and Werner J. Heinz and Meinolf Karthaus and Stefan W. Krause and William Krüger and Georg Maschmeyer and Olaf Penack and Jörg Ritter and Markus Ruhnke and Michael Sandherr and Michal Sieniawski and Jörg-Janne Vehreschild and Hans-Heinrich Wolf and Andrew J. Ullmann}, year={2008}, month={Dec.}, pages={113-122} }